At a glance
ClinicalIndex Comparison RecordN/ACompleted· 6,896 enrolled
Drug / intervention
5ARI + ABdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
In Brief
An observational study evaluating 5ARI + AB for Prostatic Hyperplasia. Completed, enrolled 6,896 participants.
Detailed Summary
This retrospective study aims to assess the economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI and alpha-blocker (AB) combination therapy. Both the Integrated Health Care Information Solutions and PharMetrics databases will be utilized for this study (2000-2007).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Hyperplasia
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
Primary CompletionJan 2010
First PostedApr 2011
TodayJul 2026
First PostedApr 11, 2011
Enrollment StartNov 1, 2009
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.2 years ago
Interventions
5ARI + ABdrug
5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin